Synergy Pharmaceuticals, Inc Common Stock
SGYP
SGYP was delisted on the 7th of March, 2019.
12 hedge funds and large institutions have $1K invested in Synergy Pharmaceuticals, Inc Common Stock in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 79 closing their positions.
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
87% less funds holding
Funds holding: 89 → 12 (-77)
97% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 79
100% less capital invested
Capital invested by funds: $4.12M → $1K (-$4.12M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$23.7K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$8.3K |
| 3 |
BWA
BDO Wealth Advisors
Jacksonville,
Florida
|
+$1.02K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.38M |
| 2 |
State Street
Boston,
Massachusetts
|
-$495K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$361K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$281K |
| 5 |
JG
Jefferies Group
New York
|
-$195K |
SGYP Hedge Fund Activity: Q1 2019 in Review
12 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q1 2019, worth a combined $1K — down 100% from $4.12M a quarter earlier.
Sellers outnumbered buyers: 79 funds closed out of SGYP and 2 opened new positions — a net loss of 77 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $23.7K. The largest seller was BlackRock, exiting entirely with an estimated $1.38M sold.
- 12 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q1 2019, down from 89 in Q4 2018.
- Funds reported $1K of Synergy Pharmaceuticals, Inc Common Stock stock for Q1 2019, down 100% quarter-over-quarter.
- 2 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q1 2019 and 79 closed out, a net change of -77 holders.
- The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q1 2019 was Tower Research Capital (TRC), an estimated $23.7K added.
- The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q1 2019 was BlackRock, an estimated $1.38M sold.
Based on aggregated 13F filings for Q1 2019.